Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
8 hedge funds and large institutions have $6.29M invested in Celyad Oncology SA American Depositary Shares in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 2 closing their positions.
94% more capital invested
Capital invested by funds: $3.24M → $6.29M (+$3.05M)
0% more funds holding
Funds holding: 8 → 8 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KI
Kapitalo Investimentos
Sao Paulo,
Brazil
|
+$35.5K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$12.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$20.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$15.3K |
| 3 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$8.04K |
| 4 |
Millennium Management
New York
|
-$5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4.15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FIG
1
Fortress Investment Group
New York
| $6.23M | – | – | – |
|
|
KI
2
Kapitalo Investimentos
Sao Paulo,
Brazil
| $29.8K | +$35.5K | +31,326 | New |
|
|
3
Citadel Advisors
Miami,
Florida
| $15.3K | -$15.3K | -13,534 | -45% |
|
|
TSS
4
Two Sigma Securities
New York
| $10.6K | +$12.5K | +11,032 | New |
|
5
National Bank of Canada
Montreal,
Quebec, Canada
| $3.09K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $2.04K | -$4.15K | -3,663 | -63% |
|
7
Wells Fargo
San Francisco,
California
| $546 | – | – | – |
|
|
8
Morgan Stanley
New York
| $96 | -$20.6K | -18,200 | -99% |
|
|
OMC
9
Old Mission Capital
Chicago,
Illinois
| – | -$8.04K | -16,319 | Closed |
|
|
10
Millennium Management
New York
| – | -$5K | -10,993 | Closed |
|
CYAD Hedge Fund Activity: Q1 2023 in Review
8 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q1 2023, worth a combined $6.29M — up 94% from $3.24M a quarter earlier.
Fund positioning in CYAD was balanced in Q1 2023: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 3 trimmed.
The largest buyer was Kapitalo Investimentos, opening a new position worth an estimated $35.5K. The largest seller was Morgan Stanley, cutting an estimated $20.6K.
- 8 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $6.29M of Celyad Oncology SA American Depositary Shares stock for Q1 2023, up 94% quarter-over-quarter.
- 2 funds opened new Celyad Oncology SA American Depositary Shares positions in Q1 2023 and 2 closed out, a net change of 0 holders.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q1 2023 was Kapitalo Investimentos, an estimated $35.5K added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q1 2023 was Morgan Stanley, an estimated $20.6K sold.
Based on aggregated 13F filings for Q1 2023.